CURT CIVIN, M.D.
Osteopathic Medicine at Wolfe St, Baltimore, MD

7767202, Aug 3, 2010

Mar 18, 2002

10/471559

Drew M. Pardoll - Brookeville MD, US
Linzhao Cheng - Columbia MD, US
Yan Cui - New Orleans LA, US
Curt I Civin - Towson MD, US
Katherine Whartenby - Baltimore MD, US

The Johns Hopkins University - Baltimore MD

A61K 48/00

424 9321, 424 932, 435375

The invention provides methods and compositions for the modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory molecules. The invention includes bi-cistronic lentiviral expression vectors adapted for antigen expression in antigen presenting cells for use in DNA vaccines directed against pathogens and tumor antigens as well as for the treatment of autoimmune disease and for the establishment of antigen tolerance.

5081030, Jan 14, 1992

Apr 25, 1989

7/342938

Curt I. Civin - Baltimore MD

The Johns Hopkins University - Baltimore MD

C12N 508, A61K 3528

4352402

The present invention comprises a process for release from the cell-receptor complex of positively selected cells in viable, functional condition, where a ligand involved in the particular receptor-ligand interaction utilized for the affinity purification is selectively attacked by one or more degradative enzymes specific for that ligand. A resulting cell suspension can be obtained substantially free of receptor material. This invention, in one embodiment, contemplates a method for positive stem cell selection, utilizing anti-MY10 and immunomagnetic microspheres to isolate CD34-positive marrow cells and employing an enzyme to release micropheres from the isolated CD34-positive cells. Reproducible enzymatic cleaving of immunomagnetic microspheres from MY10-positive cells can be achieved by brief treatment of the preparation with papain or chymopapain. The isolated CD34-positive cells are particularly desirable for bone marrow transplantation.

5130144, Jul 14, 1992

Mar 22, 1991

7/673721

Curt I. Civin - Baltimore MD

The Johns Hopkins University - Baltimore MD

A61K 3528, C12N 508

424577

Monoclonal antibodies that recognize a stage-specifc antigen on immature human marrow cells are provided. These antibodies are useful in methods of isolating cell suspensions from human blood and marrow that can be employed in bone marror transplantation. Cell suspensions containing human pluripotent lympho-hematopoietic stem cells are also provided, as well as theraputic methods employing the cell suspensions.

5705625, Jan 6, 1998

Dec 15, 1994

8/357598

Curt I. Civin - Baltimore MD
Donald Small - Baltimore MD
Meredith G. Safford - Baltimore MD

The Johns Hopkins University School of Medicine - Baltimore MD

C12N 1509, C12N 1552

536 235

A novel protein tyrosine kinase, JAK3, and a polynucleotide sequence encoding JAK3 polypeptide are disclosed herein. JAK3 is a new member of the JAK family of protein tyrosine kinases which are important in regulation of cellular proliferation and differentiation. Also disclosed are therapeutic methods utilizing JAK3 polypeptide and polynucleotide sequences.

4965204, Oct 23, 1990

Jun 1, 1987

7/055942

Curt I. Civin - Baltimore MD

The Johns Hopkins University - Baltimore MD

C12N 500, C07K 1500, A61K 3900

43524027

Monoclonal antibodies that recognize a stage-specific antigen on immature human marrow cells are provided. These antibodies are useful in methods of isolating cell suspensions from human blood and marrow that can be employed in bone marrow transplantation. Cell suspensions containing human pluripotent lympho-hematopoietic stem cells are also provided, as well as therapeutic methods employing the cell suspensions.

7799528, Sep 21, 2010

Aug 9, 2005

11/199665

Curt I. Civin - Baltimore MD, US

The Johns Hopkins University - Baltimore MD

C12Q 1/68

435 6

The invention is based at least in part on the discovery of novel group of genes and/or their encoded gene products that are differentially represented in two substantially enriched CD34/CD38/Lin and CD34/[CD38/Lin] hematopoietic cell populations isolated from normal human bone marrow, cord blood, and peripheral blood stem cell preparations.

5618709, Apr 8, 1997

Jan 14, 1994

8/183211

Alan M. Gewirtz - Philadelphia PA
Donald Small - Baltimore MD
Curt I. Civin - Baltimore MD

University of Pennsylvania - Philadelphia PA
The Johns Hopkins University - Baltimore MD

C12N 1500, C07H 2104

4351723

Oligonucleotides are provided having a nucleotide sequence complementary to at least a portion of the mRNA transcript of the STK-1 gene. These "antisense" oligonucleotides are hybridizable to the STK-1 mRNA transcript. Such oligonucleotides are useful in treating neoplastic diseases characterized by activation of STK-1 gene expression. The oligonucleotides are also useful as bone marrow purging agents in the treatment of leukemia and metastasized neoplasms.

2004013, Jul 8, 2004

Feb 25, 2004

10/471881

Curt Civin - Towson MD, US
Daniel Drachman - Stevenson MD, US
Katherine Whartenby - Baltimore MD, US
Drew Pardoll - Brookville MD, US

A61K048/00, C12N005/08

424/093210, 435/372000

The invention provides methods and compositions utilizing FasL armed donor graft cells to reduce or eliminate host allogeneic or xenogeneic graft rejection, and FasL armed host cells to reduce or eliminate graft versus host disease.

5035994, Jul 30, 1991

Sep 7, 1990

7/580337

Curt I. Civin - Baltimore MD

The Johns Hopkins University - Baltimore MD

A01N 102, A61M 3700, C12Q 100, G01N 3353

435 2

Monoclonal antibodies that recognize a stage-specific antigen on immature human marrow cells are provided. These antibodies are useful in methods of isolating cell suspensions from human blood and marrow that can be employed in bone marrow transplantation. Cell suspensions containing human pluripotent lympho-hematopoietic stem cells are also provided, as well as therapeutic methods employing the cell suspensions.